# A Study Of IMM47 In Subjects With Advanced Solid Tumors

> **NCT05985083** · PHASE1 · UNKNOWN · sponsor: **ImmuneOnco Biopharmaceuticals (Shanghai) Inc.** · enrollment: 48 (estimated)

## Conditions studied

- Oncology

## Interventions

- **DRUG:** IMM47

## Key facts

- **NCT ID:** NCT05985083
- **Lead sponsor:** ImmuneOnco Biopharmaceuticals (Shanghai) Inc.
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2023-08-18
- **Primary completion:** 2024-12-26
- **Final completion:** 2025-01-23
- **Target enrollment:** 48 (ESTIMATED)
- **Last updated:** 2023-10-04

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05985083

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05985083, "A Study Of IMM47 In Subjects With Advanced Solid Tumors". Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/clinical/NCT05985083. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*